Aernoud Fiolet

154 Chapter 5 Table S6A Key End Points and Their Components Analyzed with Two Competing Risk Models End point Colchicine (N = 2762) Placebo (N = 2760) Cause-specific Hazard Ratio (95% CI) PValue no. (%) no. (%) Primary end point Cardiovascular death, myocardial infarction*, ischemic stroke or ischemia-driven coronary revascularization 187 (6.8) 264 (9.6) 0.69 (0.57-0.83) <0.001 Secondary end points (ranked) Cardiovascular death, myocardial infarction* or ischemic stroke 115 (4.2) 157 (5.7) 0.72 (0.57-0.92) 0.007 Myocardial infarction* or ischemia- driven coronary revascularization 155 (5.6) 224 (8.1) 0.67 (0.55-0.83) <0.001 Cardiovascular death or myocardial infarction* 100 (3.6) 138 (5.0) 0.71 (0.55-0.92) 0.010 Ischemia-driven coronary revascularization 135 (4.9) 177 (6.4) 0.75 (0.60-0.94) 0.012 Myocardial infarction* 83 (3.0) 116 (4.2) 0.70 (0.53-0.93) 0.014 Ischemic stroke 16 (0.6) 24 (0.9) 0.66 (0.35-1.25) 0.198 Death from any cause 73 (2.6) 60 (2.2) 1.21 (0.86-1.71) Cardiovascular death 20 (0.7) 25 (0.9) 0.80 (0.44-1.44) Additional end points† The primary end point of the first LoDoCo trial ‡ 201 (7.3) 290 (10.5) 0.67 (0.56-0.81) New onset or first recurrence of atrial fibrillation or atrial flutter 126 (4.6) 148 (5.4) 0.84 (0.66-1.07) Deep vein thrombosis and/or pulmonary embolism 17 (0.6) 16 (0.6) 1.06 (0.53-2.10) All myocardial infarction§ 85 (3.1) 117 (4.2) 0.72 (0.54-0.95) New onset diabetes¶ 34 (1.2) 49 (1.8) Not applicable